Community Corner | Published:

Tracking the insidious course of Alzheimer's disease

Nature Medicine volume 18, pages 13421343 (2012) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N. Engl. J. Med. 10.1056/NEJMoa1202753 (11 July 2012).

  2. 2.

    et al. Hypothetical model of dynamic biomarkers of Alzheimer's pathological cascade. Lancet Neurol. 9, 119–128 (2010).

  3. 3.

    et al. Anti-Ab therapeutics in Alzheimer's disease: The need for a paradigm shift. Neuron 69, 203–213 (2011).

  4. 4.

    et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. J. Am. Med. Assoc. 277, 793–799 (1997).

  5. 5.

    et al. Pre-dementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 10, 213–220 (2011).

  6. 6.

    et al. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models. Science 335, 1503–1506 (2012).

  7. 7.

    US Food and Drug Administration. Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. (2007).

Download references

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm.2922

Authors

    Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing